Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
Yves Michiels,
Nadhira Houhou-Fidouh,
Gilles Collin,
Jérôme Berger,
Evelyne Kohli
Affiliations
Yves Michiels
Community Pharmacy, Center for Primary Care and Public Health (Unisanté) Lausanne 1011, University of Lausanne, 1015 Lausanne, Switzerland
Nadhira Houhou-Fidouh
Laboratoire de Virologie, Hôpital Bichat, Sorbonne Paris Cité, Université Paris Diderot, AP-HP, 75018 Paris, France
Gilles Collin
Laboratoire de Virologie, Hôpital Bichat, Sorbonne Paris Cité, Université Paris Diderot, AP-HP, 75018 Paris, France
Jérôme Berger
Community Pharmacy, Center for Primary Care and Public Health (Unisanté) Lausanne 1011, University of Lausanne, 1015 Lausanne, Switzerland
Evelyne Kohli
UMR INSERM/uB/AGROSUP 1231, Team 3 HSP-Pathies, Labellisée Ligue Nationale Contre le Cancer and Laboratoire d’Excellence LipSTIC, 21000 Dijon, France
Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.
